ENOV vs OFIX
ENOV: A medical technology company providing a comprehensive continuum of orthopedic care, from injury prevention and rehabilitation products to surgical reconstructive implants. OFIX: Orthofix develops and distributes orthopedic and spine fixation devices for trauma, fracture care, and bone reconstruction across global surgical markets.
Side-by-side fundamentals
| Metric | ENOV | OFIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.55 | $11.02 | |
| Market cap as of 2026-07-23 | $1.5B | $446M | |
| PEG as of 2026-07-23 | -0.04 | n/a | |
| Net margin as of 2026-07-23 | -49.9% | -7.3% | OFIX higher |
| Gross margin as of 2026-07-23 | +60.4% | +70.8% | OFIX higher |
| Operating margin as of 2026-07-23 | -47.1% | -5.7% | OFIX higher |
| ROE as of 2026-07-23 | -60.1% | -13.4% | OFIX higher |
| ROA as of 2026-07-23 | -26.6% | -7.0% | OFIX higher |
| Debt / equity as of 2026-07-23 | 0.90 | 0.54 | OFIX lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.0% | +2.6% | ENOV higher |
| Revenue CAGR (3y) SEC XBRL | +12.9% | +21.3% | OFIX higher |
| Beta as of 2026-07-23 | 1.47 | 0.70 | |
| 1-year return as of 2026-07-22 close | +3.0% | -0.7% | ENOV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.